Synendos Therapeutics AG is a biopharmaceutical company founded in April 2019 as a spin-off of the University of Bern.
Synendos develops an innovative therapeutic approach based upon first-in-class inhibitors (small molecules) that modulate a new drug target (not yet published). The inhibitors were designed and developed at the University of Bern starting from an in silico screening of 12 million compounds which was followed by a thorough med chem programme in collaboration with a CRO.
The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the brain.
Our mission is to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Barfüsserplatz 3, Basel,bs 4051,switzerland
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- synendos.com
- Keywords
- 🔹 C Wire.
- HQ
- Basel, BS
Synendos Therapeutics Ag Questions
Synendos Therapeutics Ag's website is synendos.com
Synendos Therapeutics Ag's LinkedIn profile is https://ch.linkedin.com/company/synendos
Synendos Therapeutics Ag has
12 employees.
View email and phone details for 12
employees at Synendos Therapeutics Ag.
Synendos Therapeutics Ag's industry is
Pharmaceutical Manufacturing
Synendos Therapeutics Ag's top competitors are
Noema Pharma,
Endogena Therapeutics, Inc.,
Haya Therapeutics,
Engimmune Therapeutics,
Glycoera Ag,
Muvon Therapeutics Ag,
Cutiss Ag,
Araris Biotech Ag,
Alentis Therapeutics,
Tolremo Therapeutics.
Synendos Therapeutics Ag's categories are Pharmaceutical Manufacturing
Synendos Therapeutics Ag's founding year is 2019
